Nicht aus der Schweiz? Besuchen Sie lehmanns.de

Neuroblastoma

M.A. Hayat (Herausgeber)

Buch | Hardcover
262 Seiten
2011
Springer (Verlag)
978-94-007-2417-4 (ISBN)

Lese- und Medienproben

Neuroblastoma -
CHF 224,65 inkl. MwSt
  • Versand in 10-15 Tagen
  • Versandkostenfrei
  • Auch auf Rechnung
  • Artikel merken
Introduction of new technologies and their applications to neuroblastoma diagnosis, treatment, and therapy assessment are explained. Targets for therapeutic intervention in neuroblastoma are identified, including targeting multidrug resistance in this cancer.
Introduction of new technologies and their applications to neuroblastoma diagnosis, treatment, and therapy assessment are explained. Role of molecular ghenetics in diagnosis and therapy for neuroblastoma patients is detailed. Molecular detection of minimal residual neuroblastoma is described. Magnetic resonance imaging and  spectroscopy are detailed for diagnosing this solid, extracranial cancer. Targets for therapeutic intervention in neuroblastoma are identified, including targeting multidrug resistance in this cancer. Ornithine decarboxylase and polyamines are novel targets for therapeutic intervention. The effectiveness of chemotherapy with oral irinotecan and temozolomide is explained. The role of transcription factors (GATA) in neuroblastoma pregression is  also included.

Preface.-1. Introduction. I Diagnosis and biomarkers.-2. Pediatric cns neuroblastoma: magnetic resonance imaging and spectroscopy.-3. Pediatric neuroblastoma-associated opsoclonus-myoclonus-ataxia syndrome: early diagnosis.-4. Neuroblastoma mouse model.-5. Orbital metastasis in neuroblastoma patients.-6. Pediatric neuroblastoma: molecular detection of minimal residual disease.-7. A comprehensive tissue microarray-based fish screen of alk gene in neuroblastomas. II Therapy.-8. Neuroblastoma: triptolide therapy.-9. Neuroblastoma: ornithine decarboxylase and polyamines are novel targets for therapeutic intervention.-10. Neuroblastoma: antibody-based immunotherapy.-11. Targeting multidrug resistance in neuroblastoma.-12. Neuroblastoma: perspectives for the use of il-21 in immunotherapy.-13. Neuroblastoma: role of hypoxia and hypoxia inducible factors in tumor progression.-14. Neuroblastoma: role of gata transcription factors.-15. Neuroblastoma: role of mycn/bmil pathway in neuroblastoma.-16. Neuroblastoma: role of clusterin as a tumor suppressor gene.-17. Refractory neuroblastoma cells: statins target atp binding cassette-transporters.-18. Neuroblastoma: dosimetry for mibg therapies.-19. Advanced neuroblastoma: role of alk mutations.-20. Pediatric neuroblastoma: treatment with oral irinotecan and temozolomide. III Prognosis.-21. Genomic profiling of neuroblastoma tumors- prognostic impact of genomic aberrations.-22. Neuroblastoma patients: plasma growth factor mildkine as a prognostic growth factor.-23. Pediatric neuroblastoma: role of tgfbi (keratoepithelin).-24. Role of bone marrow infiltration detected by sensitive methods in patients with localized neuroblastoma. Index

Erscheint lt. Verlag 3.11.2011
Reihe/Serie Pediatric Cancer ; 1
Zusatzinfo XVIII, 262 p.
Verlagsort Dordrecht
Sprache englisch
Maße 178 x 254 mm
Themenwelt Medizin / Pharmazie Medizinische Fachgebiete Chirurgie
Medizin / Pharmazie Medizinische Fachgebiete Neurologie
Medizin / Pharmazie Medizinische Fachgebiete Onkologie
Medizin / Pharmazie Medizinische Fachgebiete Pädiatrie
Medizinische Fachgebiete Radiologie / Bildgebende Verfahren Radiologie
Medizin / Pharmazie Studium
ISBN-10 94-007-2417-9 / 9400724179
ISBN-13 978-94-007-2417-4 / 9789400724174
Zustand Neuware
Haben Sie eine Frage zum Produkt?
Mehr entdecken
aus dem Bereich
Röntgen-Thorax-Diagnostik

von Matthias Hofer; Matthias Hofer; Lars Kamper …

Buch | Softcover (2023)
Didamed Verlag
CHF 55,85